Análise do perfil de expressão gênica de linhagens epiteliais mamárias humanas submetidas ao tratamento com rapamicina associada à doxorrubicina

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  2011-04-14

• Fields of study

  Not labeled

• Identifiers
  DOI 10.11606/T.5.2011.TDE-24052011-122633
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• Genome profiling of ERBB2-amplified breast cancers

  2010cited by this paper
• Deregulation of Rab5 and Rab4 proteins in p85R274A-expressing cells alters PDGFR trafficking.

  2010cited by this paper
• Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells - interplay of ErbB and IGF1 signalling through IGFBP3 regulation

  2010cited by this paper
• Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins

  2010cited by this paper
• Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers.

  2010cited by this paper
• Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

  2009cited by this paper
• Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables

  2008cited by this paper
• Enhanced anti‐cancer effect of a phosphatidylinositol‐3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status

  2008cited by this paper
• CRM1-mediated nuclear export of proteins and drug resistance in cancer.

  2008cited by this paper
• Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

  2008cited by this paper
• Blockade of the phosphatidylinositol-3-kinase–Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated

  2007cited by this paper
• Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.

  2007cited by this paper
• Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer

  2007cited by this paper
• 4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis

  2007cited by this paper
• mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex

  2007cited by this paper
• Targeted Deletion of MKK4 Gene Potentiates TNF-Induced Apoptosis through the Down-Regulation of NF-κB Activation and NF-κB-Regulated Antiapoptotic Gene Products1

  2007cited by this paper
• Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

  2007cited by this paper
• Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.

  2006cited by this paper
• Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.

  2006cited by this paper
• Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy.

  2006cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• mTOR and cancer: insights into a complex relationship

  2006cited by this paper
• Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.

  2006cited by this paper
• Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine

  2006cited by this paper
• Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells

  2006cited by this paper
• Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

  2006cited by this paper
• Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase–activated protein kinase 2 in mediating DNA damage–induced cell cycle arrest: implications for cancer therapy

  2006cited by this paper
• The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells

  2006cited by this paper
• Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of β1-integrins

  2006cited by this paper
• HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

  2006cited by this paper
• The proteasome: a novel target for anticancer therapy

  2006cited by this paper
• Transcriptome characterization of human mammary cell lines expressing different levels of ERBB2 by serial analysis of gene expression.

  2006cited by this paper
• Restraining PI3K: mTOR signalling goes back to the membrane.

  2005cited by this paper
• Emerging role of RAB GTPases in cancer and human disease.

  2005cited by this paper
• Rheb binds and regulates the mTOR kinase.

  2005cited by this paper
• Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells

  2005cited by this paper
• Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

  2005cited by this paper
• PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle.

  2005cited by this paper
• Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer

  2005cited by this paper
• Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.

  2005cited by this paper
• The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

  2005cited by this paper
• mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes*

  2005cited by this paper
• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.

  2005cited by this paper
• Growing roles for the mTOR pathway.

  2005cited by this paper
• Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway*

  2005cited by this paper
• Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma.

  2004cited by this paper
• The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

  2004cited by this paper
• The multifaceted role of mTOR in cellular stress responses.

  2004cited by this paper
• From polyploidy to aneuploidy, genome instability and cancer

  2004cited by this paper
• Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells

  2004cited by this paper
• Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

  2004cited by this paper
• Improved high-performance liquid chromatography assay of doxorubicin: Detection of circulating aglycones in human plasma and comparison with thin-layer chromatography

  2004cited by this paper
• AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression*

  2004cited by this paper
• mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

  2004cited by this paper
• Determinants of Rapamycin Sensitivity in Breast Cancer Cells

  2004cited by this paper
• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  2004cited by this paper
• mTOR as a positive regulator of tumor cell responses to hypoxia.

  2004cited by this paper
• Autocrine Signalling Through erbB Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines

  2003cited by this paper
• The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer

  2003cited by this paper
• Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

  2003cited by this paper
• cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells

  2003cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells

  2003cited by this paper
• Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

  2002cited by this paper
• Control of Ser2448 Phosphorylation in the Mammalian Target of Rapamycin by Insulin and Skeletal Muscle Load*

  2002cited by this paper
• mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

  2002cited by this paper
• Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells

  2002cited by this paper
• Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

  2002cited by this paper
• Akt regulates growth by directly phosphorylating Tsc2

  2002cited by this paper
• The protein kinase B/Akt signalling pathway in human malignancy.

  2002cited by this paper
• A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

  2001cited by this paper
• HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.

  2001cited by this paper
• Internal ribosome entry sites in eukaryotic mRNA molecules.

  2001cited by this paper
• A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

  2000cited by this paper
• Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• New model of ErbB‐2 over‐expression in human mammary luminal epithelial cells

  1999cited by this paper
• NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase

  1999cited by this paper
• eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation.

  1999cited by this paper
• Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.

  1999cited by this paper
• Deciphering the fluorescence signature of daunomycin and doxorubicin.

  1998cited by this paper
• Regulation of cell death protease caspase-9 by phosphorylation.

  1998cited by this paper
• Induction of sensitivity to doxorubin and etoposide by transfection of MCF-7 breast cancer cells with here β-2

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

  1997cited by this paper
• Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k

  1997cited by this paper
• Mechanism of activation of protein kinase B by insulin and IGF‐1.

  1996cited by this paper
• Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP

  1996cited by this paper
• Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

  1996cited by this paper
• Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

  1995cited by this paper
• Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

  1995cited by this paper
• Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature‐sensitive SV40 T‐antigen construct

  1994cited by this paper
• Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression.

  1993cited by this paper
• A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients.

  1989cited by this paper
• Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.

  1988cited by this paper
• Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

  1988cited by this paper
• Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.

  1987cited by this paper

• No citing papers are available for this paper.